首页> 外文期刊>Antiviral Research >A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2
【24h】

A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2

机译:SARS日冕病毒刺突蛋白受体结合结构域的六肽阻止病毒通过人类受体ACE2进入宿主细胞

获取原文
获取原文并翻译 | 示例
       

摘要

In vitro infection of Vero E6 cells by SARS coronavirus (SARS-CoV) is blocked by hexapeptide Tyr-Lys-Tyr-Arg-Tyr-Leu. The peptide also inhibits proliferation of coronavirus NL63. On human cells both viruses utilize angiotensin-converting enzyme 2 (ACE2) as entry receptor. Blocking the viral entry is specific as alpha virus Sindbis shows no reduction in infectivity. Peptide 438YKYRYL 443 is part of the receptor-binding domain (RBD) of the spike protein of SARS-CoV. Peptide libraries were screened by surface plasmon resonance (SPR) to identify RBD binding epitopes. 438YKYRYL 443 carries the dominant binding epitope and binds to ACE2 with K D=46μM. The binding mode was further characterized by saturation transfer difference (STD) NMR spectroscopy and molecular dynamic simulations. Based on this information the peptide can be used as lead structure to design potential entry inhibitors against SARS-CoV and related viruses.
机译:六肽Tyr-Lys-Tyr-Arg-Tyr-Leu可以阻断SARS冠状病毒(SARS-CoV)对Vero E6细胞的体外感染。该肽还抑制冠状病毒NL63的增殖。在人类细胞上,两种病毒均利用血管紧张素转换酶2(ACE2)作为进入受体。阻断病毒进入是特定的,因为α病毒Sindbis并未显示出传染性降低。肽438YKYRYL 443是SARS-CoV突突蛋白的受体结合域(RBD)的一部分。通过表面等离振子共振(SPR)筛选肽库,以鉴定RBD结合表位。 438YKYRYL 443携带显性结合表位,并以K D =46μM与ACE2结合。结合模式通过饱和转移差异(STD)NMR光谱和分子动力学模拟进一步表征。基于此信息,该肽可用作前导结构,以设计针对SARS-CoV和相关病毒的潜在进入抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号